Analysis of Oesophageal Neuroendocrine Tumour Outcomes Abstract #1500

Introduction: Oesophageal Neuroendocrine Tumours(NETs) are rare neoplasms accounting for <2% of Gastroenteropancreatic NET(GEP NETs).
Aim(s): To present our patients' group clinicopathological features, treatment and prognosis.
Materials and methods: Retrospective analysis from a GEP NET database of 1700 patients treated from October 2007 to November 2015.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
Keywords: oesophageal nec

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1678 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)
Introduction: GEJ-NEN is mostly poorly differentiated NEC with poor prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors: Zhang P, Lu M, Shen L, Wang W, ...
#443 Neuroendocrine Carcinoma (NEC) and Composite Exocrine-Neuroendocrine Carcinoma (CENEC) of the Stomach: A Clinicopathological Review of 58 Cases
Introduction: NEC of the stomach is an uncommon tumor accounting for 0.5% of all gastric carcinomas and about 6% of gastric NETs. CENEC contain both areas of NEC and conventional carcinoma. The histological diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Vladimir Khomyakov
#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies
Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Authors: Krieg A, Riemer J C, Dizdar L, Mersch S, ...
Keywords: GEP-NEC
#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.